Hypoxia in head and neck cancer: how much, how important?
HL Janssen, KM Haustermans… - Head & Neck: Journal …, 2005 - Wiley Online Library
Background. Hypoxia develops in tumors because of a less ordered, often chaotic, and leaky
vascular supply compared with that in normal tissues. In preclinical models, hypoxia has …
vascular supply compared with that in normal tissues. In preclinical models, hypoxia has …
[PDF][PDF] Vascular liver disorders (II): portal vein thrombosis
J Hoekstra, HL Janssen - Neth J Med, 2009 - njmonline.nl
Portal vein thrombosis (PVT) is a rare disorder that is associated with a variety of underlying
conditions, of which liver cirrhosis, malignancy and myeloproliferative disorders are the most …
conditions, of which liver cirrhosis, malignancy and myeloproliferative disorders are the most …
[PDF][PDF] Vascular liver disorders (I): diagnosis, treatment and prognosis of Budd-Chiari syndrome
J Hoekstra, HL Janssen - Neth J Med, 2008 - njmonline.nl
Thrombosis involving the liver vasculature is rare but constitutes a potentially life-threatening
situation. Budd-Chiari syndrome (BCS) is characterised by thrombosis of the hepatic …
situation. Budd-Chiari syndrome (BCS) is characterised by thrombosis of the hepatic …
Miravirsen dosing in chronic hepatitis C patients results in decreased micro RNA‐122 levels without affecting other micro RNA s in plasma
MH Van der Ree, AJ Van Der Meer… - Alimentary …, 2016 - Wiley Online Library
Background Micro RNA ‐122 (miR‐122) is an important host factor for hepatitis C virus
replication. Administration of miravirsen, an anti‐miR‐122 oligonucleotide, resulted in a dose …
replication. Administration of miravirsen, an anti‐miR‐122 oligonucleotide, resulted in a dose …
Long Term Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection is Safe and Well Tolerated and Associated with Durable Virologic Response …
P Marcellin, EJ Gane, R Flisiak, HN Trinh, J Petersen… - Hepatology, 2014 - journals.lww.com
Background: Through 5 years of treatment with tenofovir disoproxil fumarate (TDF) in mostly
naïve patients, we reported sustained viral suppression with regression of fibrosis, and …
naïve patients, we reported sustained viral suppression with regression of fibrosis, and …
Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment
HL Janssen, G Gerken, V Carreño, P Marcellin… - Hepatology, 1999 - journals.lww.com
Interferon alfa (IFN-α) is the primary treatment for chronic hepatitis B. The standard duration
of IFN-α therapy is considered 16 weeks; however, the optimal treatment length is still poorly …
of IFN-α therapy is considered 16 weeks; however, the optimal treatment length is still poorly …
Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome
JH Smalberg, SD Murad, E Braakman, PJ Valk… - …, 2006 - haematologica.org
We studied the etiology, diagnosis and natural course of myeloproliferative disease (MPD) in
40 consecutive patients with Budd-Chiari syndrome (BCS). In 38% of the BCS patients with …
40 consecutive patients with Budd-Chiari syndrome (BCS). In 38% of the BCS patients with …
HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies
M van Tilborg, SH Al Marzooqi, WWL Wong… - The Lancet …, 2018 - thelancet.com
Background Direct-acting antivirals for chronic hepatitis C (HCV) infection have reduced the
need for on-treatment HCV RNA monitoring. We assessed the accuracy and cost …
need for on-treatment HCV RNA monitoring. We assessed the accuracy and cost …
Resistance of hypoxic cells to ionizing radiation is influenced by homologous recombination status
D Sprong, HL Janssen, C Vens, AC Begg - International Journal of …, 2006 - Elsevier
Purpose: To determine the role of DNA repair in hypoxic radioresistance. Methods and
Materials: Chinese hamster cell lines with mutations in homologous recombination (XRCC2, …
Materials: Chinese hamster cell lines with mutations in homologous recombination (XRCC2, …
Changing perspectives in portal vein thrombosis.
HL Janssen - Scandinavian Journal of gastroenterology …, 2000 - europepmc.org
The aetiology of portal vein thrombosis (PVT) is heterogeneous. Important primary risk
factors for PVT are cirrhosis, hepatobiliary malignancies and pancreatitis. Newly discovered …
factors for PVT are cirrhosis, hepatobiliary malignancies and pancreatitis. Newly discovered …